BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alisertib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Alisertib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06095505-3378@assetmemo.bio
DTSTAMP:20261121T004545Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Alisertib: Phase 2 readout est. (NCT06095505)
DESCRIPTION:Alisertib\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study o
 f Alisertib in Patients With Extensive Stage Small Cell Lung Cancer\nEstim
 ated primary completion: 30 October 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/alisertib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06095505
URL:https://assetmemo.bio/drug/alisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06369285-3378@assetmemo.bio
DTSTAMP:20261121T004545Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Alisertib: Phase 2 readout est. (NCT06369285)
DESCRIPTION:Alisertib\, phase 2.\nStudy: A Study of Alisertib in Combinatio
 n With Endocrine Therapy in Patients With HR-positive\, HER2-negative Recu
 rrent or Metastatic Breast Cancer\nEstimated primary completion: 30 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/alisertib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063692
 85
URL:https://assetmemo.bio/drug/alisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07465757-3378@assetmemo.bio
DTSTAMP:20261121T004545Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Alisertib: Phase 2 readout est. (NCT07465757)
DESCRIPTION:Alisertib\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study o
 f Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)\
 nEstimated primary completion: 31 March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/alisertib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07465757
URL:https://assetmemo.bio/drug/alisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706179-3378@assetmemo.bio
DTSTAMP:20261121T004545Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Alisertib: Phase 2 readout est. (NCT07706179)
DESCRIPTION:Alisertib\, phase 2.\nStudy: Targeting Aurora A Kinase to Overc
 ome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer\nEstimated pr
 imary completion: September 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/alisertib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07706179
URL:https://assetmemo.bio/drug/alisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
